Citron’s Left: This is ‘worse’ than Valeant – CNBC


CNBC
Citron’s Left: This is ‘worse’ than Valeant
CNBC
The head of short-selling firm Citron Research on Tuesday called for more disclosures about specialty pharmaceutical company Mallinckrodt’s main drug, criticizing the company’s model and confirming he holds a short position in its shares. Citron, which …

and more >>

Source: pharmaceutical – Google News

Sharing information is key – Pharmaceutical Business News UK. Social Commerce and Social Media Management playing a big part. Suaju Ltd